While the 1984 Act has been a boon for lower-cost generics, its goal of incentivizing new drug discovery has failed.
Peter C. Richardson
Advertisement
Articles by Peter C. Richardson
On December 8, 2012, the Supreme Court agreed to hear the Federal Trade Commission (FTC) v. Actavis, Inc. case.
Advertisement
Latest Updated Articles
- FTC v. Actavis: The Wrong End of the Telescope
Published: March 25th 2014 | Updated:
Is the Hatch-Waxman System Broken?Published: January 6th 2016 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Merck Planning $70 Billion Investment for US Expansion
2
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
